Global Health Platform Alkion’s in vitro bioproduction platform, enabled by AI robotics and scalable bioreactors, supports rapid, flexible production of plant-based APIs, complex extracts and recombinant proteins. This offers a compelling path for vaccine manufacturers, NGOs and government health programs seeking high-volume, cost-effective supply with sustainability at the core. The QS super immunity booster program represents a potential collaboration angle for vaccine efficacy initiatives and global distribution while preserving biodiversity.

Sustainable Production Advantage Carbon-neutral operations and resource-efficient production provide a strong ESG value proposition for pharma, nutraceuticals and agrifood customers aiming to strengthen supply chain resilience. Alkion can offer co-development and supply agreements for plant-based APIs and ingredients that balance scale, cost efficiency and biodiversity preservation. This positioning supports customers pursuing green procurement and circular bioeconomy initiatives.

Cannabinoid Licensing Ready With an established cannabinoid R&D licence, Alkion can support CNS therapies, pain management and other pharma applications through contract development and manufacturing. Target customers include biotech firms, pharmaceutical companies and research institutions seeking licensed capability to produce cannabinoid APIs and standardized extracts under regulated processes. Fast onboarding and scalable manufacturing capacity can shorten development timelines for cannabinoid products.

Agrifood Protein Opportunity An exotic plant-derived healthy sweet protein provides a high-value ingredient for food and pharma applications, appealing to manufacturers of sweeteners, nutraceuticals and biotech products seeking clean labels and functional benefits. The initiative offers a potential revenue uplift for farmers through collaboration and diversified crops. This aligns with demand for sustainable, plant-based ingredients across multiple markets.

Funding & Partnerships Recognition by European and global programs such as I-Lab, I-Nov and EIC Accelerator signals validation and access to funding networks for joint ventures, consortia and grant-funded projects. This opens sales opportunities through co-funded research partnerships, technology licensing discussions and accelerator-backed commercialization programs. Engaging with NGOs, universities and government programs can accelerate pilot projects into scalable commercial deals.